Decipher
the gut
The gut is a black box where products are being transformed. At Cryptobiotix, we decipher this black box in the lab. We elucidate how ingested actives are affected by digestion and interact with the gut microbiome, impacting overall well-being. With innovative ex vivo and in vitro gut simulations and a dedicated team, we keep pushing the boundaries of preclinical research in the field.
Preclinical data
you can trust
Products intended to improve gut health frequently fail in clinical trials, due to unreliable data from in vitro models. Cryptobiotix was founded as preclinical CRO to bridge this gap, by developing the ex vivo SIFR® technology pipeline:
- Uniquely validated to predict clinical outcomes
- High throughput to investigate many conditions in parallel
- Advanced data visualisation and interpretation
Services
At Cryptobiotix, we have redefined the approach to gut microbiome research. Utilising our innovative SIFR® technology, we offer a solution that combines high throughput and validated predictivity.
This modular technology simulates the entire gastrointestinal tract as needed for your project. If relevant, the upper GI digestion is implemented, before the ex vivo gut fermentation is recreated. By simulating gut conditions ex vivo, we overcome the limitations of traditional in vitro methods, providing actionable insights quickly and cost-effectively.
Our approach enhances biorelevance, increases throughput, and clarifies key findings through advanced data interpretation, fast-tracking and de-risking your product development.
SIFR® technology
Systemic Intestinal Fermentation Research
swipe
SIFR® in screening mode
In screening mode, swiftly evaluate numerous candidates early in discovery phase and identify the most promising ones. Get quick and targeted insights into the efficacy of your products, dosing, synergies, and many more aspects.
SIFR® in prism mode
In prism mode, characterise the interplay between your products and the gut microbiome to provide unparalleled insights into mechanisms of action, efficacy, and interindividual variations. De-risk your product development with a fully validated and predictive ex vivo simulation, increasing your chances of success at clinical stage and providing you with all the data necessary to support IP and regulatory dossier submissions.
Applications
We simulate the gastrointestinal tract of humans across many ages and physiologies (healthy, diseased) as well as animals. We have extensive experience investigating all types of products in vitro and ex vivo, from pure ingredients to complex matrices.
Gastrointestinal simulation model
Infant & toddler
Child & adult
Elderly
Disease & dysbiosis
Cat
Dog
Poultry
Swine
Product types
Fibres & prebiotics
Probiotics & LBPs
Postbiotics & extracts
Drugs
Whole foods
Why work with us?
1. De-risk your product development
Predictive insights from the SIFR® de-risk your product development by increasing your chances of clinical success.
2. Gain unprecedented insights in your product
Unravel the mechanism of action of your products and understand how they can contribute to gut health and overall well-being.
3. Shorten time to market
Obtain accurate results and gain critical insights to move forward quickly with IP applications and regulatory dossiers.
Publications
Explore our research findings and insights into the gut microbiome. We’re committed to sharing our discoveries with the scientific community to advance knowledge in this field.
Meet our team
Cryptobiotix is a dynamic company, built around a team of dedicated individuals that share a common vision. Challenging the status quo, empowerment, doing what feels right, and curiosity for the unknown. Since 2021, our team grew to more than 10 employees, passionate about enabling discoveries that can improve lives.
Want to join our team?
Aurélien Baudot holds a double MSc in Bioscience Engineering and Artificial Intelligence. Over the past decade, he has built broad expertise across the biotech sector, specialising in molecular biology, lab automation, advanced analytics, and gut microbiome research. As CEO of Cryptobiotix, he leads the company’s strategic direction and commercial growth, working closely with clients to understand their scientific questions and shape the solutions of tomorrow.
Dr. Pieter Van den Abbeele is an expert in gut microbiome research and co-inventor of Cryptobiotix’s proprietary SIFR® technology pipeline. As CSO, he drives the scientific vision and innovation pipeline, ensuring the company’s solutions remain at the forefront of preclinical gastrointestinal simulation. His work bridges the gap between preclinical and clinical research, helping global partners in food, feed, biotech, and pharma to accelerate product development while reducing the reliance on animal testing.
Dr. Lien Van den Bossche oversees all operations at Cryptobiotix, ensuring excellence, quality control, and compliance with regulatory standards. With a background in biotechnology and extensive hands-on experience in microbiome research, she manages the day-to-day execution of projects, the planning of resources, and drives the continuous optimisation of lab workflows. Her leadership ensures that client studies are delivered on time, with the highest scientific and technical standards.
Dr. Ingmar van Hengel leads the global business development efforts at Cryptobiotix, building strategic partnerships and identifying new market opportunities in the food, feed, biotech and pharma sectors. With a scientific and commercial background, he bridges the gap between client needs and the company’s advanced preclinical solutions. Ingmar works closely with R&D and operations teams to design tailored study approaches, helping clients bringing their products faster and more consistently to the market.
De-risk your product
development today
Contact form
We’re always happy to hear from potential customers, partners, and collaborators.